Physician profile
Kathryn Davis
NPI 1073678181
$59,470.46
in general payments reported to CMS, 2019-2025
14 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,572 · 2020: $10K · 2021: $150 · 2022: $3,521 · 2023: $11K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $3,262 · Honoraria: $2,464 · Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,257.01 |
| Travel and Lodging | $3,261.86 |
| Honoraria | $2,463.50 |
| Food and Beverage | $2,048.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $13,656.17 | 2024-2025 | |
| Eisai INC. | $10,206.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,384.99 | 2024 | |
| Neurelis, INC. | $5,314.74 | 2023 | Valtoco |
| Ucb Sa | $5,287.29 | 2025 | |
| Ucb, INC. | $3,373.85 | 2022-2025 | Fintepla |
| Sk Life Science, INC. | $3,254.35 | 2020-2025 | |
| Biocodex, INC. | $2,662.04 | 2023 | Diacomit |
| Greenwich Biosciences, INC. | $2,482.06 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $2,250.00 | 2023 | Zonisade |
| Vertex Pharmaceuticals Incorporated | $960.00 | 2019-2023 | |
| Spark Therapeutics, INC. | $485.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $117.00 | 2022 | |
| Medtronic USA, INC. | $36.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.